Industry Updates

The FDA and generic drug makers reached an agreement that would require the companies to pay at least $299 million per year to accelerate generic drug approvals.

Drug companies are threatening to delay listing their products on the pharmaceutical benefits scheme in protest at changes to how drugs are being selected, a Senate inquiry has heard.

 Measurable brain chemistry changes may appear 10 to 20 years before the first detectable memory and thinking impairments among people with a rare genetic form of Alzheimer's, according to new research presented today at the Alzheimer's Association® International Conference 2011 (AAIC 2011) in Paris.

Analysis of opinions drawn from leading pharmaceutical industry executives